Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
![]() |
The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspectivePloS one, 2018-05, Vol.13 (5), p.e0197670-e0197670 [Peer Reviewed Journal]COPYRIGHT 2018 Public Library of Science ;COPYRIGHT 2018 Public Library of Science ;2018 van Asten et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2018 van Asten et al 2018 van Asten et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0197670 ;PMID: 29772018Full text available |
2 |
Material Type: Article
|
![]() |
Treatment regimens for administration of anti‐vascular endothelial growth factor agents for neovascular age‐related macular degenerationCochrane database of systematic reviews, 2020-05, Vol.2020 (5), p.CD012208 [Peer Reviewed Journal]Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ;EISSN: 1465-1858 ;EISSN: 1469-493X ;DOI: 10.1002/14651858.CD012208.pub2 ;PMID: 32374423Full text available |
3 |
Material Type: Article
|
![]() |
Anti‐vascular endothelial growth factor for diabetic macular oedema: a network meta‐analysisCochrane database of systematic reviews, 2018-10, Vol.2018 (10), p.CD007419 [Peer Reviewed Journal]Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ;EISSN: 1465-1858 ;EISSN: 1469-493X ;DOI: 10.1002/14651858.CD007419.pub6 ;PMID: 30325017Full text available |
4 |
Material Type: Article
|
![]() |
Anti‐vascular endothelial growth factor for neovascular age‐related macular degenerationCochrane database of systematic reviews, 2019-03, Vol.2019 (3), p.CD005139 [Peer Reviewed Journal]Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ;EISSN: 1465-1858 ;EISSN: 1469-493X ;DOI: 10.1002/14651858.CD005139.pub4 ;PMID: 30834517Full text available |
5 |
Material Type: Article
|
![]() |
Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LUMINOUS studyPloS one, 2020-01, Vol.15 (1), p.e0227557-e0227557 [Peer Reviewed Journal]COPYRIGHT 2020 Public Library of Science ;COPYRIGHT 2020 Public Library of Science ;2020 Hamilton et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 Hamilton et al 2020 Hamilton et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0227557 ;PMID: 31961888Full text available |
6 |
Material Type: Article
|
![]() |
Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD StudyPloS one, 2016-05, Vol.11 (5), p.e0153052-e0153052 [Peer Reviewed Journal]COPYRIGHT 2016 Public Library of Science ;COPYRIGHT 2016 Public Library of Science ;2016 Schauwvlieghe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2016 Schauwvlieghe et al 2016 Schauwvlieghe et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0153052 ;PMID: 27203434Full text available |
7 |
Material Type: Article
|
![]() |
Advances in the treatment of diabetic retinopathyJournal of diabetes and its complications, 2019-12, Vol.33 (12), p.107417, Article 107417 [Peer Reviewed Journal]2019 ;Copyright © 2019. Published by Elsevier Inc. ;Copyright Elsevier Limited Dec 2019 ;ISSN: 1056-8727 ;EISSN: 1873-460X ;DOI: 10.1016/j.jdiacomp.2019.107417 ;PMID: 31669065Full text available |
8 |
Material Type: Article
|
![]() |
Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trialThe Lancet (British edition), 2015-12, Vol.386 (10011), p.2395-2403 [Peer Reviewed Journal]Elsevier Ltd ;2015 Elsevier Ltd ;Copyright © 2015 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Dec 12, 2015 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(15)00345-1 ;PMID: 26431823 ;CODEN: LANCAOFull text available |
9 |
Material Type: Article
|
![]() |
Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS studyPloS one, 2020-12, Vol.15 (12), p.e0244183 [Peer Reviewed Journal]COPYRIGHT 2020 Public Library of Science ;COPYRIGHT 2020 Public Library of Science ;2020 Holz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2020 Holz et al 2020 Holz et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0244183 ;PMID: 33378369Full text available |
10 |
Material Type: Article
|
![]() |
A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degenerationBritish journal of ophthalmology, 2016-07, Vol.100 (7), p.914-917 [Peer Reviewed Journal]Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/. ;Copyright: 2016 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2015-306987 ;PMID: 26516125 ;CODEN: BJOPALFull text available |
11 |
Material Type: Article
|
![]() |
Aflibercept for neovascular age‐related macular degenerationCochrane database of systematic reviews, 2016-02, Vol.2016 (2), p.CD011346-CD011346 [Peer Reviewed Journal]Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ;EISSN: 1465-1858 ;EISSN: 1469-493X ;DOI: 10.1002/14651858.CD011346.pub2 ;PMID: 26857947Full text available |
12 |
Material Type: Article
|
![]() |
A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degenerationScientific reports, 2017-08, Vol.7 (1), p.9196-8, Article 9196 [Peer Reviewed Journal]2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2017 ;ISSN: 2045-2322 ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-017-09632-0 ;PMID: 28835685Full text available |
13 |
Material Type: Article
|
![]() |
A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edemaGraefe's archive for clinical and experimental ophthalmology, 2017-03, Vol.255 (3), p.463-473 [Peer Reviewed Journal]Springer-Verlag Berlin Heidelberg 2016 ;Graefe's Archive for Clinical and Experimental Ophthalmology is a copyright of Springer, 2017. ;ISSN: 0721-832X ;EISSN: 1435-702X ;DOI: 10.1007/s00417-016-3472-1 ;PMID: 27632215Full text available |
14 |
Material Type: Article
|
![]() |
Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedemaCochrane database of systematic reviews, 2018-04, Vol.2018 (4), p.CD011599 [Peer Reviewed Journal]Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ;EISSN: 1465-1858 ;EISSN: 1469-493X ;DOI: 10.1002/14651858.CD011599.pub2 ;PMID: 29669176Full text available |
15 |
Material Type: Article
|
![]() |
A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United KingdomAdvances in therapy, 2017-03, Vol.34 (3), p.703-712 [Peer Reviewed Journal]The Author(s) 2017 ;ISSN: 0741-238X ;EISSN: 1865-8652 ;DOI: 10.1007/s12325-017-0483-1Digital Resources/Online E-Resources |
16 |
Material Type: Article
|
![]() |
Cost-Utility Analysis of VEGF Inhibitors for Treating Neovascular Age-Related Macular DegenerationAmerican journal of ophthalmology, 2020-10, Vol.218, p.225-241 [Peer Reviewed Journal]2020 Elsevier Inc. ;Copyright © 2020 Elsevier Inc. All rights reserved. ;2020. Elsevier Inc. ;ISSN: 0002-9394 ;EISSN: 1879-1891 ;DOI: 10.1016/j.ajo.2020.05.029 ;PMID: 32565050Full text available |
17 |
Material Type: Article
|
![]() |
Moorfields AMD database report 2: fellow eye involvement with neovascular age-related macular degenerationBritish journal of ophthalmology, 2020-05, Vol.104 (5), p.684-690 [Peer Reviewed Journal]Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0007-1161 ;EISSN: 1468-2079 ;DOI: 10.1136/bjophthalmol-2019-314446 ;PMID: 31611234Full text available |
18 |
Material Type: Article
|
![]() |
Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular DegenerationJournal of ocular pharmacology and therapeutics, 2018-12, Vol.34 (10), p.700-709 [Peer Reviewed Journal]David Callanan, et al. 2018; Published by Mary Ann Liebert, Inc. 2018 ;ISSN: 1080-7683 ;EISSN: 1557-7732 ;DOI: 10.1089/jop.2018.0062 ;PMID: 30412448Full text available |
19 |
Material Type: Article
|
![]() |
Emerging therapeutic strategies for unmet need in neovascular age-related macular degenerationJournal of translational medicine, 2023-02, Vol.21 (1), p.133-133, Article 133 [Peer Reviewed Journal]2023. The Author(s). ;COPYRIGHT 2023 BioMed Central Ltd. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2023 ;ISSN: 1479-5876 ;EISSN: 1479-5876 ;DOI: 10.1186/s12967-023-03937-7 ;PMID: 36810060Full text available |
20 |
Material Type: Article
|
![]() |
Relationship between stereopsis and vision-related quality of life following intravitreal ranibizumab injections for central retinal vein occlusionScientific reports, 2021-10, Vol.11 (1), p.20475-20475, Article 20475 [Peer Reviewed Journal]2021. The Author(s). ;The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 2045-2322 ;EISSN: 2045-2322 ;DOI: 10.1038/s41598-021-00094-z ;PMID: 34650099Full text available |